Last reviewed · How we verify
NCT04660422: ACP-COVID
Advance Care Planning: Communicating With Outpatients for Vital Informed Decision
trial testing VitalTalk communication skills training in Advanced Care Planning in 42,019 participants. Completed in 31 December 2021.
31 December 2021
Quick facts
| Lead sponsor | Dana-Farber Cancer Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 42,019 |
| Start date | 15 December 2020 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- VitalTalk communication skills training
- ACP Decisions Video Program
- Intervention training:
- Medical Record Review
Conditions studied
- Advanced Care Planning — all drugs for Advanced Care Planning →
- Shared Decision Making — all drugs for Shared Decision Making →
- Video Decision Aids — all drugs for Video Decision Aids →
- Communication Skills — all drugs for Communication Skills →
Sponsor
Dana-Farber Cancer Institute
Who can join
65 and older, any sex, with Advanced Care Planning or Shared Decision Making. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Pre-Post, open-cohort design, pragmatic trial with 150 clinicians and will evaluate the effectiveness of the use of telehealth Advanced Care Planning (ACP) Program by comparing ACP documentation among 13,000 patients over 65
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Association of an Advance Care Planning Video and Communication Intervention With Documentation of Advance Care Planning Among Older Adults: A Nonrandomized Controlled Trial.
Volandes AE, Zupanc SN, Paasche-Orlow MK, Lakin JR, et al · · 2022 · cited 34× · PMID 35201306 · DOI 10.1001/jamanetworkopen.2022.0354 -
Structural Barriers to Well-grounded Advance Care Planning for the Seriously Ill: a Qualitative Study of Clinicians' and Administrators' Experiences During a Pragmatic Trial.
Murray GF, Lakin JR, Paasche-Orlow MK, Tulsky JA, et al · · 2023 · cited 6× · PMID 37488368 · DOI 10.1007/s11606-023-08320-2
Verify or expand the search:
- PubMed search for NCT04660422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Care Planning
Currently open trials in the same condition.
- NCT06238063 — Implementing a Nurse-led Advance Care Planning (ACP) Intervention in Residential Care Homes · NA · recruiting
Other Dana-Farber Cancer Institute trials
Trials by the same sponsor.
- NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
- NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
- NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
- NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
- NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04660422 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
- Last refreshed: 5 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04660422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing